Staff

Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

AUSTIN, Texas, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...

Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination

-- NCI will lead the Phase 1 study using Gritstone’s proprietary “off the shelf” vaccine technology for mutant KRAS solid...

Monopar Announces Camsirubicin Clinical Program Update – Improved Side Effect Profile Seen to Date Compared to Doxorubicin

WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...

Hyperfine, Inc. Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop® Portable MR Imaging® System

Latest Swoop® software improves image quality for DWI imaging of the brainGUILFORD, Conn., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Hyperfine,...

Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Topline trial results expected mid-March 2023NEWTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical...

Anika Announces First Surgeries Performed Using the New RevoMotion™ Reverse Shoulder Arthroplasty System and Commences Limited Market Release in the United States

RevoMotion significantly expands Anika’s shoulder arthroplasty portfolio and provides a new solution in the over $800 million U.S. reverse shoulder...

Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards

MINNEAPOLIS, Minn, Feb. 13, 2023 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive...

error: Content is protected !!